![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 8-May-2013[ | E-mail |
Share ] Contact: Greyling Peoples
g.peoples@elsevier.com
31-204-853-323
Elsevier
Amsterdam, May 8, 2013 Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of a clinical guide by the European Menopause and Andropause Society (EMAS) in the journal Maturitas on endometrial assessment in peri and postmenopausal women with summary recommendations.
The main onus of endometrial assessment is to exclude carcinoma of the endometrium and premalignant endometrial hyperplasia. Assessment of the endometrium in the absence of bleeding should be limited to women at high risk of endometrial cancer. Transvaginal ultrasound scanning (TVS) is used for initial assessment to be followed by endometrial biopsy to be undertaken as an outpatient procedure if possible. Hysteroscopy allows direct visualization of the endometrial cavity and any focal lesions. Should results be inconclusive and abnormal or postmenopausal bleeding persist, transvaginal ultrasound should be repeated and hysteroscopy performed.
These and other recommendations presented in EMAS' clinical guide are published in the article: 'EMAS clinical guide: Assessment of the endometrium in peri and postmenopausal women', by Eva Dreisler, Lars Grnlund Poulsen, Sofie Leisby Antonsen, Iuliana Ceausu, Herman Depypere, C. Tamer Erel, Irene Lambrinoudaki, Faustino R. Prez-Lpez, Tommaso Simoncini, Florence Tremollieres, Margaret Rees and Lian Ulrich (10.1016/j.maturitas.2013.03.011).The article appears in Maturitas Volume 75, Issue 2 (June 2013), published by Elsevier.
###
Notes for Editors
Full text of the article is available to credentialed journalists upon request, contact newsroom@elsevier.com. For further details about the clinical guide or to contact the authors or EMAS, contact: g.peoples@elsevier.com, +31 20 485 3323
About the European Menopause and Andropause Society (EMAS)
EMAS promotes the study of midlife health through its journal, congresses, schools and website and encourages the exchange of research and professional experience between members. Using a range of activities and through its affiliates, EMAS aims to guarantee and provide the same standard of education and information throughout Europe on midlife health in both genders. Recognizing the issues arising from increased longevity the society also provides articles, patient information, web resources, and referrals for healthcare providers in the field and keeps its members up-to-date. For more information go to: http://www.emas-online.org
About Maturitas
Maturitas is an international multidisciplinary peer reviewed scientific journal of midlife health and beyond, publishing original research, reviews, consensus statements and guidelines. The scope encompasses all aspects of postreproductive health in both genders ranging from basic science to health and social care. http://www.maturitas.org/
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 8-May-2013[ | E-mail |
Share ] Contact: Greyling Peoples
g.peoples@elsevier.com
31-204-853-323
Elsevier
Amsterdam, May 8, 2013 Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of a clinical guide by the European Menopause and Andropause Society (EMAS) in the journal Maturitas on endometrial assessment in peri and postmenopausal women with summary recommendations.
The main onus of endometrial assessment is to exclude carcinoma of the endometrium and premalignant endometrial hyperplasia. Assessment of the endometrium in the absence of bleeding should be limited to women at high risk of endometrial cancer. Transvaginal ultrasound scanning (TVS) is used for initial assessment to be followed by endometrial biopsy to be undertaken as an outpatient procedure if possible. Hysteroscopy allows direct visualization of the endometrial cavity and any focal lesions. Should results be inconclusive and abnormal or postmenopausal bleeding persist, transvaginal ultrasound should be repeated and hysteroscopy performed.
These and other recommendations presented in EMAS' clinical guide are published in the article: 'EMAS clinical guide: Assessment of the endometrium in peri and postmenopausal women', by Eva Dreisler, Lars Grnlund Poulsen, Sofie Leisby Antonsen, Iuliana Ceausu, Herman Depypere, C. Tamer Erel, Irene Lambrinoudaki, Faustino R. Prez-Lpez, Tommaso Simoncini, Florence Tremollieres, Margaret Rees and Lian Ulrich (10.1016/j.maturitas.2013.03.011).The article appears in Maturitas Volume 75, Issue 2 (June 2013), published by Elsevier.
###
Notes for Editors
Full text of the article is available to credentialed journalists upon request, contact newsroom@elsevier.com. For further details about the clinical guide or to contact the authors or EMAS, contact: g.peoples@elsevier.com, +31 20 485 3323
About the European Menopause and Andropause Society (EMAS)
EMAS promotes the study of midlife health through its journal, congresses, schools and website and encourages the exchange of research and professional experience between members. Using a range of activities and through its affiliates, EMAS aims to guarantee and provide the same standard of education and information throughout Europe on midlife health in both genders. Recognizing the issues arising from increased longevity the society also provides articles, patient information, web resources, and referrals for healthcare providers in the field and keeps its members up-to-date. For more information go to: http://www.emas-online.org
About Maturitas
Maturitas is an international multidisciplinary peer reviewed scientific journal of midlife health and beyond, publishing original research, reviews, consensus statements and guidelines. The scope encompasses all aspects of postreproductive health in both genders ranging from basic science to health and social care. http://www.maturitas.org/
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-05/e-emp050813.php
bloom box obama sweet home chicago accenture match play george washington carver king cake fun. hepatitis c symptoms
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.